Business
Half-year Report
GENinCode Plc reported a 15% increase in first-half revenues, reaching £1.60m compared to £1.39m in the first half of 2024, driven by growth in the UK, EU, and US markets. The company successfully completed a £3.7m fundraising to support expansion. The adjusted EBITDA loss, excluding unrealized forex loss, was £2.07m, slightly higher than the £2.05m loss in the prior period. Cash reserves stood at £2.44m as of June 30, 2025, a notable increase from £1.11m at the end of 2024. However, due to slower NHS growth and FDA approval delays, the company anticipates full-year revenue to be approximately £3.3m, with similar cost levels expected in the second half. Disclaimer*
About this update from Genincode Plc
[{"type":"text","content":"\n\n \n30 September 2025\nGENinCode Plc\n(\"GENinCode\", the \"Company\" or the \"Group\")\n \nInterim results statement\nStrengthening revenues in US, UK and EU\n \nOxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease (\"CVD\") and risk of ovarian cancer announces its unaudited interim results for the six months ended 30 June 2025.\n \nOperational highlights\n\n\n\n\n· Announcement of first ROCA commercial contract with NHS - University College London Hospitals NHS Foundation Trust ('UCLH') and the North Central London ('NCL') Cancer Alliance for surveillance of women at high genetic risk of ovarian cancer\n\n\n\n\n· Increasing US commercial sales of LIPID inCode® and CARDIO inCode-Score®. Over 40 US clinics and institutions now onboarded for risk assessment and preventive testing of coronary heart disease\n\n\n\n\n· While disappointing not to have received approval during the period, CARDIO inCode-Score® FDA 'De Novo' Supervisory Review was completed with agreement of outstanding deficiencies and process to submit additional information.\n· Ongoing discussions with US commercial partners for CARDIO inCode-Score test distribution\n\n\n\n\n· Inclusion of CARDIO inCode-Score® in 2025 US clinical lab fee schedule\n\n\n\n\n· NHS expansion of LIPID inCode® for FH diagnosis in North of England however, progress has been slower than expected due to the major strategic, organisational and funding changes across the NHS.\n\n\n\n\n· Growth of LIPID inCode® in University Clinic Dresden, Germany for primary care diagnosis of Familial Hypercholesterolemia (FH)\n\n\n\n\n· Growth of LIPID inCode® and THROMBO inCode® in Spain and Italy. CARDIO inCode-Score® pilot progressing in Extremadura and Catalonia regions of Spain\n· Presentations at American Society of Preventive Cardiology Annual Meeting and European Society of Cardiology World Congress on genetic modulation of cholesterol risk\n\n\n\n\n\n\n\n\n\n \nFinancial highlights\n\n\n\n\n•\n\n\nFirst half revenues increased 15% to £1.60m (30 June 2024: £1.39m), driven by growth in UK, EU and US\n\n\n\n\n•\n\n\nSuccessful completion in March o...